Ventyx Biosciences, Inc. VTYX
14.00 USD 0.00 (+0.00%)
Mar 6, 2026, 9:30 AM EST
14.00 Day range 14.00
52-week range unavailable
- YTD
- +55.04%
- 1 year
- +858.90%
Analyst view
Price target (mean) —
Ratings (0m) 5 0 buy · 5 hold · 0 sell
- Strong buy0
- Buy0
- Hold5
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 8
- 2 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.39441 | -0.49 – -0.29 | -0.41 | +3.8% | 0 | 0.0% | 4 |
| Next quarter | -0.395 | -0.51 – -0.28 | -0.39 | -1.3% | 0 | 0.0% | 2 |
| Current year | -1.48 | -1.57 – -1.37 | -1.97 | +25.0% | 0 | 0.0% | 4 |
| Next year | -1.57 | -2.08 – -1.23 | -1.48 | -5.9% | 0 | 0.0% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 8, 2026 | Oppenheimer | Downgrade | Outperform | Perform |
| Jan 8, 2026 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| Jan 8, 2026 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Jan 8, 2026 | UBS | Downgrade | Buy | Neutral |
| Jan 8, 2026 | LifeSci Capital | Downgrade | Outperform | Market Perform |
| Jan 8, 2026 | Canaccord Genuity | Downgrade | Buy | Hold |
| Jan 7, 2026 | UBS | Initiated | — | Buy |
| Nov 7, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Nov 7, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Nov 5, 2025 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| Oct 27, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Oct 1, 2025 | Clear Street | Initiated | — | Buy |
| Jan 14, 2025 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Nov 11, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Nov 8, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Oct 15, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Sep 23, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Aug 12, 2024 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 12, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Jul 30, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Jun 13, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Jun 6, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Jun 6, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Mar 13, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Mar 12, 2024 | Wells Fargo | Upgrade | Equal-Weight | Overweight |
| Mar 12, 2024 | Oppenheimer | Upgrade | Perform | Outperform |
| Mar 11, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Feb 21, 2024 | Oppenheimer | Reiterated | — | Perform |
| Dec 19, 2023 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Dec 18, 2023 | Stifel | Maintained | Hold | Hold |